| Status | Study |
| Not yet recruiting |
Study Name: Study to Evaluate Efficacy and Safety of Sunitinib in Patients With Renal Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment Condition: Clear Cell Renal Carcinoma Date: 2017-02-23 Interventions: Drug: Sunitinib Sunitinib 50 mg/d |
| Recruiting |
Study Name: Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Condition: Ovarian Clear Cell Carcinoma Endometrial Date: 2016-07-22 Interventions: Drug: Nintedanib Nintedanib (B |
| Recruiting |
Study Name: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Condition: Renal Clear Cell Carcinoma Renal Papillary Cell Carcinoma Date: 2016-02-22 Interventions: Drug: Savolitinib Other Names: |
| Active, not recruiting |
Study Name: Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Ovarian Clear Cell Adenocarcinoma Date: 2014-12-09 Interventions: Drug: Cabozantinib S-malate Gi |
| Active, not recruiting |
Study Name: Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Condition: Endometrial Clear Cell Adenocarcinoma Estrogen Receptor Negative Date: 2014-02-07 Interventions: Drug: Dasatinib Given PO |
| Recruiting |
Study Name: A Study of ENMD-2076 in Ovarian Clear Cell Cancers Condition: Ovarian Clear Cell Carcinoma Date: 2013-07-11 Interventions: Drug: ENMD-2076 |
| Recruiting |
Study Name: Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Condition: Ovarian Cancer Adverse Effects Date: 2013-03-19 Interventions: Drug: Sunitinib 37.5mg everyday from D1-D28 Other Na |
| Withdrawn |
Study Name: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Condition: Endometrioid Carcinoma Clear Cell Carcinoma Date: 2012-11-18 |
| Recruiting |
Study Name: A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Condition: Ewing Sarcoma Gastrointestinal Tumor Germ Cell Tumor Date: 2012-06-19 Interventions: Drug: alemtuzumab Patients rec |
| Completed |
Study Name: Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Condition: Ovarian Clear Cell Cystadenocarcinoma Stage III Ovarian Cancer Date: 2010-09-04 Interventions: Drug: Carboplatin Given IV |